>MNTA – Why didn't [the FDA] use Amphastar's technology? or Teva's? <
As noted in the thread on SI, there’s a serious side to this: an increased likelihood that MNTA/Sandoz will possess the sole generic Lovenox on the US market. As you know, this a precondition for the outsized earnings numbers MNTA could garner from generic Lovenox.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”